MiR-378通过联合抑制线素激活蛋白激酶通路因子来控制心脏缩
Jayavarshni Ganesan1, Deepak Ramanujam, Yassine Sassi
1Institut für Pharmakologie und Toxikologie, Technische Universität München, Munich, Germany.
Circulation
|April 30, 2013
概括
微RNA-378 (miR-378) 通过向MAPK通路来抑制心脏缩. 在疾病模型中恢复miR-378显著降低了缩和改善了心脏功能,这表明了治疗潜力.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 微RNAs调节心脏中的基因表达,与心脏疾病相关的失调.
- 微RNA-378 (miR-378) 在心脏中表达高,但主要在癌症中进行研究.
研究的目的:
- 研究miR-378在调节心肌细胞缩中的作用.
- 为了探索miR-378在心脏病中的治疗潜力.
主要方法:
- 利用分离的初级心肌细胞和体内压力过载模型 (胸前动脉收缩).
- 采用生物信息学预测,mRNA/蛋白质分析和光酶测试来识别miR-378目标.
- 使用腺相关病毒介导的基因传递用于心肌细胞向的miR-378恢复.
主要成果:
- miR-378既必要又足以抑制心肌细胞增大.
- 验证了四个关键的甲基因激活蛋白激酶 (MAPK) 途径组件作为直接的miR-378标.
- 在体内恢复miR-378显著减轻心脏缩和改善心脏功能.
结论:
- miR-378通过抑制MAPK信号通路,作为心肌细胞缩的关键调节剂.
- 针对心肌细胞的miR-378的恢复是心肌疾病的潜在治疗策略.
相关概念视频
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

